El-Lebedy Dalia, Rasheed Enas, Kafoury Mona, Abd-El Haleem Dalia, Awadallah Eman, Ashmawy Ingy
Department of Clinical and Chemical Pathology, Medical Research Division, National Research Centre, Cairo, Egypt.
J Diabetes Complications. 2016 May-Jun;30(4):580-5. doi: 10.1016/j.jdiacomp.2016.02.014. Epub 2016 Feb 21.
Anti-Apolipoprotein A-1 autoantibodies (anti-ApoA-1 IgG) represent an emerging prognostic cardiovascular marker in patients with myocardial infarction or autoimmune diseases associated with high thrombotic events. The aim of this work is to investigate the incidence of anti-apoA-1 autoantibodies in type 2 diabetes (T2DM) patients with and without CVD and to study potential association with disease risk and its effect on plasma lipid parameters.
Qualitative determination of anti-apoA-1 IgG was assayed in sera from 302 subjects classified into T2DM patients (n=102), T2DM+CVD (n=112) and healthy controls (n=88).
The incidence of anti-apoA-1 IgG was significantly higher among CVD patients (35.7%) than T2DM patients (8.8%) or control subjects (6.1%), p<0.0001. A significant association with CVD was identified (p<0.0001) and subjects who were positive for anti-apoA-1 IgG were at 8.5 times increased risk to develop CVD when compared to controls. Diabetic patients who were positive for the antibodies showed 5.7 times increased CVD risk. ROC analysis indicated anti-apoA-1 IgG as a risk biomarker for CVD in T2DM patients with an AUC value of 0.76, sensitivity of 35.7% and specificity of 91.2%. Studying the effect on lipid parameters, anti-apoA-1 IgG associated with significantly higher serum concentrations of TC and non-HDL-C in all groups and with higher concentrations of LDL-C in diabetic patients and higher TC/HDL-C ratio in CVD patients.
Our results indicate that anti-apoA-1 IgG is a cardiovascular risk biomarker in T2DM patients.
抗载脂蛋白A-1自身抗体（抗ApoA-1 IgG）是心肌梗死或与高血栓形成事件相关的自身免疫性疾病患者中一种新兴的心血管预后标志物。本研究旨在调查2型糖尿病（T2DM）合并和不合并心血管疾病（CVD）患者中抗载脂蛋白A-1自身抗体的发生率，并研究其与疾病风险的潜在关联及其对血脂参数的影响。
对302名受试者的血清进行抗ApoA-1 IgG的定性检测，这些受试者分为T2DM患者（n = 102）、T2DM + CVD患者（n = 112）和健康对照者（n = 88）。
CVD患者中抗ApoA-1 IgG的发生率（35.7%）显著高于T2DM患者（8.8%）或对照者（6.1%），p < 0.0001。确定其与CVD存在显著关联（p < 0.0001），抗ApoA-1 IgG呈阳性的受试者发生CVD的风险比对照者增加8.5倍。抗体呈阳性的糖尿病患者发生CVD的风险增加5.7倍。ROC分析表明，抗ApoA-1 IgG是T2DM患者CVD的风险生物标志物，AUC值为0.76，敏感性为35.7%，特异性为91.2%。研究其对血脂参数的影响，抗ApoA-1 IgG与所有组中显著更高的总胆固醇（TC）和非高密度脂蛋白胆固醇（non-HDL-C）血清浓度相关，与糖尿病患者中更高的低密度脂蛋白胆固醇（LDL-C）浓度以及CVD患者中更高的TC/HDL-C比值相关。
我们的结果表明，抗ApoA-1 IgG是T2DM患者的心血管风险生物标志物。
